NAD+ Sublingual

Description

NAD+ Sublingual tablets represent an alternative delivery format for Nicotinamide Adenine Dinucleotide research, designed for absorption through the sublingual mucosa. The sublingual route bypasses first-pass hepatic metabolism, which is a significant consideration for NAD+ delivery since oral ingestion subjects the molecule to extensive gastrointestinal degradation. Research has demonstrated that sublingual absorption of nucleotide-based compounds can achieve higher bioavailability compared to standard oral administration.

Each tablet contains 250mg of NAD+ in a formulation optimized for sublingual dissolution. The sublingual mucosa is highly vascularized and permeable, allowing direct absorption into the systemic circulation. Pharmacokinetic studies of sublingual NAD+ delivery have shown measurable increases in plasma NAD+ metabolites within 30 minutes of administration, compared to 1-2 hours for oral formulations with generally lower peak levels.

The non-invasive nature of sublingual delivery makes this format particularly valuable for longitudinal research protocols where repeated administration is required. Unlike injectable formulations that require reconstitution, sterile technique, and cold chain management, sublingual tablets can be stored at room temperature and administered without specialized equipment. This simplifies experimental design and reduces variables related to injection technique and reconstitution protocols.

Research applications for sublingual NAD+ mirror those of the injectable form: cellular energy metabolism, sirtuin activation, DNA repair capacity, and age-related decline in NAD+ pools. The sublingual format is particularly suited for research comparing bioavailability across delivery routes, studying dose-response relationships in accessible models, and protocols requiring frequent or chronic administration. Each tablet is manufactured under cGMP conditions with consistent dosing across the batch.

Quality control for NAD+ sublingual tablets includes HPLC purity analysis of the active compound, dissolution testing to verify appropriate release kinetics, content uniformity testing across the batch, and stability testing under various storage conditions. This product is supplied as 30 tablets per bottle, each containing 250mg NAD+.

Composition

• Compound: NAD+ (Nicotinamide Adenine Dinucleotide)
• Format: Sublingual tablets
• Dosage: 250mg per tablet
• Quantity: 30 tablets per bottle
• Total NAD+: 7,500mg per bottle
• Purity: >98% (HPLC)
• Excipients: Mannitol, cellulose, magnesium stearate

Storage

• Store in a cool, dry place away from direct sunlight.
• Keep at room temperature (15-25°C) — no refrigeration required.
• Keep bottle tightly sealed between uses.
• Shelf life: 18 months from date of manufacture.
• Do not expose to excessive humidity or heat.

Certificate of Analysis

Every batch of NAD+ Sublingual tablets sold by Pepspan undergoes rigorous third-party testing. Our Certificate of Analysis (COA) includes HPLC purity analysis, dissolution testing, content uniformity, and microbiological testing. COA documentation is available upon request for any batch number.

Current Batch: Pending first shipment

Every batch of NAD+ Sublingual sold by Pepspan is independently tested by Janoshik Analytical (Prague, Czech Republic). HPLC purity analysis, mass spectrometry, and amino acid sequencing are performed for each shipment. Reports are batch-specific — not generic.

Research Disclaimer

This product is intended for laboratory research use only. It is not a drug, food, cosmetic, or dietary supplement. NAD+ Sublingual tablets are not approved for human or veterinary use by any regulatory agency. By purchasing this product, you confirm that you are a qualified researcher and that this product will be used exclusively for legitimate scientific research purposes.